中文版 | English
Title

二期翻修治疗培养阴性膝关节假体周围感染

Alternative Title
Treatment of culture-negative periprosthetic joint infection after total knee arthroplasty
Author
Publication Years
2021
DOI
Source Title
ISSN
1674-134X
Volume15Issue:6Pages:680-686
Abstract
目的:回顾性分析二期翻修治疗细菌培养结果为阴性的膝关节假体周围感染(PJI)的临床结果。方法:检索2010年至2017年西京医院关节外科收治的人工膝关节置换术后PJI,排除急性感染、培养阳性和一期翻修的病例,纳入慢性感染且微生物培养结果为阴性的病例共27例,所有患者均采用二期翻修手术治疗,术中使用抗生素骨水泥,术后给予6周抗生素治疗(静脉输入3周+口服左氧氟沙星+利福平胶囊3周)的方案。感染持续时间、是否使用抗生素等因素与窦道形成的相关性采用logistic回归分析。结果:纳入的27个病例中,感染治愈共26例(96.3%),其中保留关节功能的24例(88.9%),经关节融合治愈的患者2例,感染控制失败的1例(3.7%)。性别、年龄、是否使用抗生素、感染持续时间、C反应蛋白、血沉、白细胞计数、中性粒细胞百分比、D-二聚体等因素与窦道形成无显著相关性(均为P>0.05)。结论:采用二期翻修+万古霉素/妥布霉素联合抗生素骨水泥,术后采用静滴头孢菌素的抗感染治疗,可以获得较好的治愈率并保留关节功能;但因缺乏对照且病例数较少,该方案的有效性尚需进一步论证。
Keywords
URL[Source Record]
Language
Chinese
SUSTech Authorship
Others
Data Source
WanFang
WanFangID
zhgjwkzz202106005
PDF urlhttps://zhgjwkzz.cma-cmc.com.cn/CN/10.3877/cma.j.issn.1674-134X.2021.06.005
Citation statistics
Cited Times [WOS]:0
Document TypeJournal Article
Identifierhttp://kc.sustech.edu.cn/handle/2SGJ60CL/401969
DepartmentSouthern University of Science and Technology Hospital
Affiliation
1.710032 西安,空军军医大学附属西京医院骨科
2.518000 深圳,南方科技大学医院骨科医学部
Recommended Citation
GB/T 7714
王华溢,杨重飞,陈永锋,等. 二期翻修治疗培养阴性膝关节假体周围感染[J]. 中华关节外科杂志(电子版),2021,15(6):680-686.
APA
王华溢.,杨重飞.,陈永锋.,孙强.,朱锦宇.,...&朱庆生.(2021).二期翻修治疗培养阴性膝关节假体周围感染.中华关节外科杂志(电子版),15(6),680-686.
MLA
王华溢,et al."二期翻修治疗培养阴性膝关节假体周围感染".中华关节外科杂志(电子版) 15.6(2021):680-686.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Export to Excel
Export to Csv
Altmetrics Score
Google Scholar
Similar articles in Google Scholar
[王华溢]'s Articles
[杨重飞]'s Articles
[陈永锋]'s Articles
Baidu Scholar
Similar articles in Baidu Scholar
[王华溢]'s Articles
[杨重飞]'s Articles
[陈永锋]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[王华溢]'s Articles
[杨重飞]'s Articles
[陈永锋]'s Articles
Terms of Use
No data!
Social Bookmark/Share
No comment.

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.